Everything below concerns lyophilization. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-09-29. Where a claim depends on a specific study, the study is described rather than over-claimed.
Early research on PT-141 grew out of work on melanotan II, a related cyclic peptide studied for pigmentation. Investigators observed that centrally acting melanocortin agonists also influenced sexual behaviour in animal models, and the programme shifted toward that endpoint. A nasal formulation was evaluated in clinical trials but showed inconsistent absorption, and later studies used subcutaneous administration instead. Regulatory approval in the United States followed in 2019 for a defined population of premenopausal women with acquired, generalised hypoactive sexual desire disorder. That approval was specific to that group rather than a broad indication.
Bremelanotide acts as a non-selective agonist at melanocortin receptors, with reported activity at MC1R, MC3R, MC4R and MC5R. The proposed basis for its central effects is activation of MC4R populations in the hypothalamus, a region associated with appetite and reproductive signalling. Because the peptide carries a net positive charge and polar side chains, it does not cross biological membranes freely, which is one reason oral administration is not the standard route. Effects generally appear within an hour of parenteral administration and are described as centrally mediated rather than peripheral.
Regulatory status varies by jurisdiction, where approved prescription products, compounded preparations and research-grade material are treated as distinct categories with different documentation requirements. Suppliers of research material commonly issue a certificate of analysis listing purity, identity and sometimes endotoxin content. Independent verification by a third-party laboratory is often recommended because self-reported figures are difficult to check. Literature discussions usually state the source, purity and storage conditions of the material used, since these details affect reproducibility. Analysts note that a reported purity figure does not by itself describe biological activity.
Lyophilised peptide is generally held below minus twenty degrees Celsius, protected from light and moisture, because hydrolysis and oxidation accumulate faster at ambient temperature. Once reconstituted, solutions are typically kept between two and eight degrees Celsius and used within a short window defined by the supplier. Repeated freeze-thaw cycles are avoided since they promote aggregation and loss of soluble material. Container material matters as well, because peptides adsorb to certain plastics and glass surfaces at low concentration. Stability figures supplied by a vendor apply only to the specific lot and buffer that were tested.
Identity and purity are usually established with reversed-phase high-performance liquid chromatography combined with mass spectrometry. A gradient of water and acetonitrile containing trifluoroacetic acid is a common mobile phase, and ultraviolet detection near 214 nanometres responds to the peptide backbone. Mass spectrometry confirms the expected molecular mass and helps reveal truncation or oxidation products. Purity is reported as a peak-area percentage, a figure that depends on the wavelength and gradient used, so values from different laboratories are not always directly comparable. Peptide mapping and amino acid analysis provide additional confirmation when required.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Cyclic heptapeptide | Synthetic analogue of alpha-MSH |
| Molecular formula | C50H68N14O10 | Acetate salt form commonly reported |
| Molecular mass | ~1025 Da | Monoisotopic value near 1025.2 |
| Key structural motif | Lactam bridge | Asp side chain to Lys side chain |
| Solid appearance | White to off-white powder | Lyophilised and hygroscopic |
Reverse-phase high-performance liquid chromatography is the standard method for assessing purity. Mass spectrometry confirms molecular identity and detects sequence variants or truncation products. Ultraviolet absorbance at 214 or 280 nm is used for quantification, with the choice depending on the peptide sequence. Method validation typically addresses linearity, limit of detection, and precision across a defined concentration range. Impurity profiling may also employ ion-exchange or size-exclusion chromatography, and these techniques complement one another.
Certificate of analysis documents usually report purity percentage, molecular weight, and appearance. Researchers verify identity by comparing observed and theoretical mass values. Chain-of-custody records and batch numbers help trace material from source to experiment. Independent verification of supplier claims is considered good practice when material identity is critical to a study. Records should include the storage history of each aliquot, and unexpected deviations in appearance or solubility warrant re-testing before use.
Development began with intranasal formulations investigated for erectile dysfunction, but blood pressure elevation limited that route and prompted a switch to subcutaneous delivery. Clinical testing then shifted toward hypoactive sexual desire disorder in premenopausal women, and a subcutaneous product received United States approval in 2019. Later trials examined other populations with mixed results, and questions about effect size, durability and patient selection remain open in the peer-reviewed literature. Research interest continues in parallel with the broader melanocortin field, where several synthetic analogues are studied together.
PT-141 is the research code for bremelanotide, a cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone. The molecule belongs to the melanocortin receptor agonist family and shows highest affinity for the MC4 receptor subtype, with weaker activity at MC1, MC3 and MC5. Its structure retains the core His-Phe-Arg-Trp sequence that defines melanocortin recognition, while cyclization and terminal modifications improve metabolic stability relative to the parent hormone. Early work classified the compound as a centrally acting agent rather than a peripherally acting vasodilator, which shaped subsequent development priorities.
Sandbuster Sand-Resistant Oil SPF 2 Tropical Deluxe SPF 4 Mega-Tan SPF 4 Mademoiselle (SPF 4, SPF 8, and SPF 15) All Day (SPF 4, SPF 8, SPF 15, SPF 30, Kids SPF 30, and Gentle Block SPF 30) SPF + Color (SPF 8, SPF 15, SPF 20) - line renamed to "Sunless Tanning Creme with Sunblock" Sunless (Light, Dark, Deep Dark, Tanning Spray Dark, and Tanning Spray Deep Dark) Apres Soleil After Sun Revitalizing Aloe Mist Apres Soleil After Sun Moisture Replenishing Lotion Orange Gelee (SPF 4, SPF 8, SPF 15, and SPF 30) Ecran Solaire (SPF 15 and SPF 30 Kids) - Canada Product development scientists at Pfizer CHCG were John A. Scott (group manager), Alice Scheiner (after sun and high-SPF products), Eric M. Stroud (sunless products), Judy Meyer, Andrew Ortega, and Mary Williams (packaging). Two innovations in 1,3-dihydroxyacetone stability were invented during this time. The entire brand was eventually divested on October 7, 1999, to Schering-Plough.
== Adverse effects == During the trials there were 5 deaths from acute liver failure and 2 other patients were saved from death by receiving a liver transplant. The toxicity of FIAU was notably delayed as the severe effects became apparent after 13 weeks of treatment. The specific toxic symptoms include: fatigue, skin rash, nausea, bone marrow suppression, seizures, pain in the arms and legs, hepatic (liver) failure (with mild jaundice), lactic acidosis (severe accumulation of lactic acid in the blood), pancreatitis, micro versicular steatosis (marked accumulation of the fat within the cells of the liver), myopathy and peripheral neuropathy. The FIAU is a clear example of direct drug-induced mitochondrial toxicity. Besides being incorporated into the viral DNA, FIAU is also incorporated into mitochondrial DNA. As FIAU is inserted into the growing chain of mitochondrial DNA replication. This leads to an inability of mitochondrial DNA polymerase γ to (further) replicate the DNA. There is a lack of DNA to provide ‘instructions’ to the mitochondria, resulting in reduction of mitochondrial respiration and the activity of mitochondrial respiratory complexes. The mitochondria no longer produce sufficient energy, causing lactic acid to form rapidly. The acute liver failure is a direct result of this cascade. The liver is an energy-intensive organ and thus the failure of its cellular power plants will quickly lead to physical decay. But this damage is not limited to only the liver, as mitochondria are found all throughout the body.
From 1946 through 1993, thirteen countries used ocean disposal or ocean dumping as a method to dispose of nuclear/radioactive waste with an approximation of 200,000 tons sourcing mainly from the medical, research and nuclear industry. Ocean floor disposal of radioactive waste has been suggested by the finding that deep waters in the North Atlantic Ocean do not present an exchange with shallow waters for about 140 years based on oxygen content data recorded over a period of 25 years. They include burial beneath a stable abyssal plain, burial in a subduction zone that would slowly carry the waste downward into the Earth's mantle, and burial beneath a remote natural or human-made island. While these approaches all have merit and would facilitate an international solution to the problem of disposal of radioactive waste, they would require an amendment of the Law of the Sea. Nuclear submarines have been lost and these vessels reactors must also be counted in the amount of radioactive waste deposited at sea. Article 1 (Definitions), 7., of the 1996 Protocol to the Convention on the Prevention of Marine Pollution by Dumping of Wastes and Other Matter, (the London Dumping Convention) states:
Summarising their findings, they conclude: "The medical notes indicate that, on admission, Dylan's bronchial disease was found to be very extensive, affecting upper, mid and lower lung fields, both left and right." The forensic pathologist, Bernard Knight, who examined the post-mortem report, concurs: "death was clearly due to a severe lung infection with extensive advanced bronchopneumonia...the severity of the chest infection, with greyish consolidated areas of well-established pneumonia, suggests that it had started before admission to hospital." Thomas died at noon on 9 November 1953, having never recovered from his coma. A nurse, and the poet John Berryman, were present with him at the time of death.
== See also == Alpha toxin Pathology Lysosomal acid lipase deficiency Peripheral membrane proteins Phospholipase A Phospholipase C Triglyceride lipase Phospholipase A2 Outer membrane phospholipase A1 Patatin-like phospholipase
Sources: en.wikipedia.org
=== 2010–2012: Early growth === Blockchain analysts estimate that Nakamoto had mined about one million bitcoins before he disappeared in 2010 and handed the network alert key and control of the code repository over to Gavin Andresen. Andresen later became lead developer at the Bitcoin Foundation, an organization founded in September 2012 to promote bitcoin. After early "proof-of-concept" transactions, the first major users of bitcoin were black markets, such as the dark web Silk Road. During its 30 months of existence, beginning in February 2011, Silk Road exclusively accepted bitcoins as payment, transacting ₿9.9 million, worth about $214 million.
Wills Professor of Physics, University of Bristol. For services to Physics. Professor Henry John Evans. For services to Medical Research. James Stuart Fair, Chairman, Dundee Teaching Hospitals NHS Trust. For services to Health Care. Jonathan Farquharson, lately Legal Commissioner, Charity Commission. Thomas Hugh Francis Farrell, , Pro-Chancellor and Chairman of Council, University of Hull. For services to Higher Education. David Geoffrey Nigel Filkin, Secretary, Association of District Councils. For services to Local Government. Stanley Fishman, President, Cinema Exhibitors' Association. For services to the Film Industry. Frederick Forsyth, Writer. For services to Literature. Michael John Ernest Frye, Chief Executive, B. Elliott plc. For services to Business. Professor Charles Albert Eric Goodhart, Professor of Banking and Finance, London School of Economics. For services to Monetary Economics. Peter James Grant, Chairman, Highlands and Islands Airports Ltd. For services to Industry. Paul Frederick Gribble. For political service. Ewan William Harper. For services to the Church of England. Derek James Harrington, Deputy Chairman and Chief Executive, Port of Felixstowe Ltd., and Director, Hutchison International Port Holdings. For services to the Ports Industry. Peregrine Andrew Morny Cavendish, Marquess of Hartington, lately Senior Steward of the Jockey Club and Chairman, British Horse Racing Board. For services to Horse Racing. David Hewitt. For services to the Community. Pamela Jean Hibbs, , Chief Nurse and Director of Quality Assurance, Royal Hospitals NHS Trust, London.
Cigarette companies have capitalized on this philosophical objection and exploited the doubts of clinicians, who consider only individual cases, on the causal link in the stochastic expression of the toxicity as an actual disease. There have been multiple court cases against tobacco companies for having researched the health effects of smoking, but having then suppressed the findings or formatted them to imply lessened or no hazard. After a ban on smoking in all enclosed public places was introduced in Scotland in March 2006, there was a 17 per cent reduction in hospital admissions for acute coronary syndrome during the ten months after the ban, compared with the ten preceding months.
are calculated for a short time frame, and the matrices for longer periods of time are calculated by assuming mutations follow a Markov chain model. The base unit of time for the PAM matrices is the time required for 1 mutation to occur per 100 amino acids, sometimes called 'a PAM unit' or 'a PAM' of time. This is precisely the duration of mutation assumed by the PAM1 matrix. The constant
Sources: en.wikipedia.org
PT-141 was the development code used for bremelanotide during its preclinical and early clinical programme. The peptide is now generally referred to by its international nonproprietary name.
The two compounds share the same cyclic core and are both non-selective melanocortin agonists. They differ chiefly at the C-terminus, where bremelanotide carries a free carboxylic acid and melanotan II a terminal amide.
Receptor binding profiles are well characterised in vitro, but the downstream pathway linking MC4R activation to behavioural effects is not fully mapped. Several intermediate neural circuits have been proposed without definitive confirmation.
Purity is normally expressed as a percentage of total peak area from a chromatographic run. The value depends on the column, gradient and detection wavelength chosen. Results generated under different conditions are therefore not always interchangeable.